New York Chronicle

Atrial Fibrillation Overview

Atrial Fibrillation is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications. During atrial fibrillation, the heart’s two upper chambers (the atria) beat chaotically and irregularly out of coordination with the two lower chambers (the ventricles) of the heart.

“Atrial Fibrillation Pipeline Insight, 2022“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atrial Fibrillation Market. 

The Atrial Fibrillation Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

Some of the key takeaways from the Atrial Fibrillation Pipeline Report:

• Companies across the globe are diligently working toward developing novel Atrial Fibrillation treatment therapies with a considerable amount of success over the years. Atrial Fibrillation Key players such as – Espero BioPharma, Vivasc Therapeutics, Hanmi Pharmaceutical, Verseon, HUYA Biosciences, Novartis, AbbVie, ARCA biopharma, Merz Pharma, and others, are developing therapies for the Atrial Fibrillation treatment 

• Atrial Fibrillation Emerging therapies such as – ESP-001, CTP-Amio, HIP-2001, VE 1902, HBI-3000, HSY 244, AGN-151607, Gencaro, Botulinum toxin A, and others are expected to have a significant impact on the Atrial Fibrillation market in the coming years.   
• In January 2022, ARCA biopharma, Inc. announced that the paper entitled “Dose Limiting, Adverse Event Associated Bradycardia with β-blocker Treatment of Atrial Fibrillation in the GENETIC-AF Trial” (William Abraham, et al) has been published in Heart Rhythm O2, a publication of the Hearth Rhythm Society
• A new patent issued to ARCA by the United States Patent and Trademark Office (USPTO) in February 2021 for use of Gencaro in treating AF in the HF population that ARCA plans to enroll in Gencaro’s planned Phase 3 development, a population that includes more than half of all HF patients in the United States and Europe 

Atrial Fibrillation Pipeline Therapeutics Assessment

• Atrial Fibrillation Assessment by Product Type
• Atrial Fibrillation By Stage and Product Type
• Atrial Fibrillation Assessment by Route of Administration
• Atrial Fibrillation By Stage and Route of Administration
• Atrial Fibrillation Assessment by Molecule Type
• Atrial Fibrillation by Stage and Molecule Type

DelveInsight’s Atrial Fibrillation Report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Atrial Fibrillation Drugs Under Different Phases of Clinical Development Include:

• ESP-001: Espero BioPharma
• CTP-Amio: Vivasc Therapeutics
• HIP-2001: Hanmi Pharmaceutical
• VE 1902: Verseon
• HBI-3000: HUYA Bioscience
• HSY 244: Novartis
• AGN-151607: AbbVie
• Gencaro: ARCA biopharma
• Botulinum toxin A: Merz Pharma 

Atrial Fibrillation Pipeline Analysis:

The Atrial Fibrillation pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the Atrial Fibrillation treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atrial Fibrillation Treatment.
• Atrial Fibrillation key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Atrial Fibrillation Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atrial Fibrillation market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Atrial Fibrillation product details are provided in the report. Download the Atrial Fibrillation pipeline report to learn more about the emerging Atrial Fibrillation therapies

Atrial Fibrillation Pipeline Market Drivers

• Rising prevalence of Atrial fibrillation
• Increase in the Adoption of Advanced Technologies

Atrial Fibrillation Pipeline Market Barriers

• Complications associated with the use of atrial fibrillation drugs
• Lack of awareness regarding medical therapy in underdeveloped and developing regions

Get a Free Sample PDF Report to know more about Atrial Fibrillation Pipeline Assessment- https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight

Scope of Atrial Fibrillation Pipeline Drug Insight    

• Coverage: Global
• Key Atrial Fibrillation Companies: Espero BioPharma, Vivasc Therapeutics, Hanmi Pharmaceutical, Verseon, HUYA Biosciences, Novartis, AbbVie, ARCA biopharma, Merz Pharma, and others
• Key Atrial Fibrillation Therapies: ESP-001, CTP-Amio, HIP-2001, VE 1902, HBI-3000, HSY 244, AGN-151607, Gencaro, Botulinum toxin A, and others
• Atrial Fibrillation Therapeutic Assessment: Atrial Fibrillation current marketed and Atrial Fibrillation emerging therapies
• Atrial Fibrillation Market Dynamics: Atrial Fibrillation market drivers and Atrial Fibrillation market barriers 

Request for Sample PDF Report for Atrial Fibrillation Pipeline Assessment and clinical trials

Table of Contents

Download Sample PDF Report to know more about Atrial Fibrillation drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/